NASDAQ:KYTH - Kythera Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.09 0.00 (0.00 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$0.09
Today's Range$0.09 - $0.09
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Receive KYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for KYTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:KYTH
CUSIP50157010
WebN/A
Phone+1-818-5874500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Kythera Biopharmaceuticals (NASDAQ:KYTH) Frequently Asked Questions

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) posted its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.34. The biopharmaceutical company earned $288 million during the quarter. View Kythera Biopharmaceuticals' Earnings History.

Has Kythera Biopharmaceuticals been receiving favorable news coverage?

News articles about KYTH stock have been trending negative on Tuesday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kythera Biopharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future.

What other stocks do shareholders of Kythera Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kythera Biopharmaceuticals investors own include Gilead Sciences (GILD), Raptor Pharmaceutical (RPTP), Bausch Health Companies (BHC), Celgene (CELG), Recro Pharma (REPH), Revance Therapeutics (RVNC), Intercept Pharmaceuticals (ICPT), Shire-Nps Pharmaceuticals (NPSP), Splunk (SPLK) and Whiting Petroleum (WLL).

How do I buy shares of Kythera Biopharmaceuticals?

Shares of KYTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kythera Biopharmaceuticals' stock price today?

One share of KYTH stock can currently be purchased for approximately $0.09.

How can I contact Kythera Biopharmaceuticals?

Kythera Biopharmaceuticals' mailing address is 27200 Agoura Rd Ste 200, AGOURA HILLS, CA 91301-5127, United States. The biopharmaceutical company can be reached via phone at +1-818-5874500.


MarketBeat Community Rating for Kythera Biopharmaceuticals (NASDAQ KYTH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KYTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KYTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel